GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Komipharm International Co Ltd (XKRX:041960) » Definitions » Tax Expense

Komipharm International Co (XKRX:041960) Tax Expense : ₩0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Komipharm International Co Tax Expense?

Komipharm International Co's tax expense for the months ended in Dec. 2024 was ₩0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩0 Mil.


Komipharm International Co Tax Expense Historical Data

The historical data trend for Komipharm International Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Komipharm International Co Tax Expense Chart

Komipharm International Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 171.15 -

Komipharm International Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Komipharm International Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Komipharm International Co  (XKRX:041960) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Komipharm International Co Tax Expense Related Terms

Thank you for viewing the detailed overview of Komipharm International Co's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Komipharm International Co Business Description

Traded in Other Exchanges
N/A
Address
1236-6 Jungwang-Dong, Sihung, Gyeonggi, KOR, 429-450
Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.

Komipharm International Co Headlines

No Headlines